Semaglutide Generic: What Really Exists in the UK Right Now

The myth that's worth correcting first: 'generic semaglutide' is widely available online

A question our prescribers hear most weeks is some version of: 'I saw generic Wegovy for a fraction of the price, is it the same thing?' It isn't. The phrase 'generic semaglutide' gets used online to describe everything from unlicensed compounded preparations to outright counterfeits, and that blurring is genuinely dangerous.

A licensed generic medicine is one that has gone through a regulatory approval process (the MHRA in the UK) to confirm it contains the correct active ingredient at the correct dose, produced to the correct standard. No such product exists for semaglutide in the UK weight-management space. Novo Nordisk holds active patent protection on semaglutide, and no competitor has received MHRA authorisation to manufacture a generic equivalent for this indication. What gets sold as 'generic semaglutide' without that authorisation is, by definition, unlicensed.

The MHRA has made this point forcefully. Enforcement actions through 2024 and 2025 resulted in the seizure of roughly 20 million doses of illegally traded weight-loss medicines worth around £45 million, and the first illicit UK site producing counterfeit tirzepatide pens was uncovered in 2025. Fake pens have been found to contain insulin rather than the labelled medicine, with obvious and serious consequences. If you want to understand more about the timeline for when semaglutide could go generic, that is a separate and genuinely interesting question, but it does not apply to anything on the market today.

What 'generic' actually means, and where semaglutide's patent stands

Patent protection gives a pharmaceutical company exclusive rights to manufacture and sell a medicine for a defined period, typically around 20 years from filing. During that window, no other manufacturer can legally produce a copy. Once patents expire, other companies can apply for authorisation to make a bioequivalent version (a generic) and competition usually brings prices down substantially.

Semaglutide's core patents are not expected to expire until somewhere in the late 2020s to early 2030s, though the exact picture is complicated: some jurisdictions will see earlier expiry on certain patent claims, and Novo Nordisk holds multiple overlapping patents covering the molecule, formulations and delivery devices. The practical upshot for UK patients is that a licensed, affordable generic Wegovy is not on the near horizon. Pages like when semaglutide will be generic cover this timeline in more detail if you want the longer view.

It is also worth being precise about what semaglutide products do exist in the UK legally. Wegovy (semaglutide 2.4mg, and now up to 7.2mg following MHRA approval in 2026) is licensed for weight management. Ozempic is also semaglutide, but it is licensed for type 2 diabetes, not weight loss. Rybelsus is oral semaglutide, again for type 2 diabetes. The oral weight-management version, Wegovy tablets, received its own MHRA approval in June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK. None of these are generics; they are all brand-name Novo Nordisk products, and patients sometimes ask us specifically about the 3ml semaglutide presentation when comparing formats and quantities available through a licensed route. You can read a fuller overview of how semaglutide works if you want to understand the medicine itself before exploring options.

Why unlicensed 'generic' products carry real clinical risk

Semaglutide is a Prescription-Only Medicine. That classification exists because appropriate use depends on clinical assessment, your BMI, your health history, your current medicines, your kidney function, whether you are pregnant or trying to conceive. A product that bypasses that process does not just bypass paperwork; it bypasses the safeguards that make the medicine appropriate for you specifically.

Beyond the regulatory issue, unlicensed preparations lack the quality controls applied to MHRA-authorised products. That means uncertain concentration, uncertain sterility, and uncertain contents. The MHRA's Yellow Card scheme exists partly so that patients and clinicians can report suspected counterfeit or substandard products, and reports have been rising. The NHS sets out the evidence base and safety profile for licensed semaglutide clearly in its semaglutide medicines page, which is a useful reference for the legitimate medicine's actual side-effect profile and contraindications.

On cost: it is true that licensed Wegovy is not cheap, and the price context around weight-loss medicines is something worth understanding properly. Our treatment page sets out what is included in a private prescription at nume (consultation, clinical review, delivery and aftercare) as a single transparent price. The question of whether a lower price elsewhere represents a saving or a risk is not rhetorical; for a prescription medicine, it is the right question to ask.

What your options actually are today

If you are looking for semaglutide for weight management in the UK, your options are Wegovy (injection or, from summer 2026, the licensed tablet) through a private prescription, or via the NHS if you meet current access criteria. NHS access is phased and criteria remain strict, our Wegovy overview explains the current landscape, including the newer 7.2mg pen approved in April 2026 that is narrowing the results gap between semaglutide and tirzepatide.

Private prescriptions are available through a GPhC-registered online pharmacy following a clinical consultation. That process (where a named, qualified prescriber reviews your information) is what makes the medicine appropriate and legal. It is not a formality. At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber the same day; you can read about how we work and verify our pharmacy on the GPhC register (registration number 9012878) if you want to check our credentials before doing anything else.

If you are weighing up Wegovy against other licensed options, our weight-loss treatment overview sets out what is available through our pharmacy clearly. Generic semaglutide is not one of those options, not because we have chosen not to stock it, but because it does not exist as a legal, safe product in the UK today.